Verve Therapeutics to Unveil Interim Data on VERVE-101 at at American Heart Association's Event
Portfolio Pulse from Benzinga Newsdesk
Verve Therapeutics announced it will present interim data from its ongoing heart-1 Phase 1b clinical trial of VERVE-101 for patients with high-risk heterozygous familial hypercholesterolemia at the American Heart Association's Scientific Sessions 2023. VERVE-101 is an investigational medicine designed to inactivate the PCSK9 gene in the liver to reduce low-density lipoprotein cholesterol. The company expects to report initial safety and pharmacodynamic data, as well as blood PCSK9 and blood LDL-C levels.
September 26, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Verve Therapeutics is set to present interim data from its ongoing clinical trial of VERVE-101. The data could potentially impact the company's stock depending on the results.
The presentation of interim data from the clinical trial of VERVE-101 is a significant event for Verve Therapeutics. The results could potentially impact the company's stock price depending on whether the data is positive or negative. However, as the data is yet to be presented, the short-term impact on the stock is uncertain.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100